16.1 Epidemiology & Control of TB, Malaria & Dengue

Epidemiology & Control of Tuberculosis, Malaria & Dengue

Communicable diseases continue to present a substantial public health challenge in India. For the UPSC Combined Medical Services (CMS) examination, a precise understanding of epidemiological triad parameters, transmission dynamics, diagnostic indicators, vector control indices, and national treatment protocols is essential.

---

1. Tuberculosis (TB) Epidemiology & Public Health Dynamics

Agent & Reservoir Factors

• Causative Agent: Mycobacterium tuberculosis (acid-fast, aerobic, slow-growing intracellular bacillus).
• Source of Infection: Open pulmonary TB cases discharging tubercle bacilli in their sputum (sputum smear-positive pulmonary cases). A single untreated smear-positive pulmonary case can infect 10–15 individuals per year in a community.
• Reservoir: Exclusively human cases. Animal reservoir (Mycobacterium bovis) is rare in India due to boiling/pasteurization of milk.
• Transmission Route: Airborne droplet nuclei (1–5 µm diameter) generated during coughing, sneezing, or speaking. Larger droplets settle rapidly, but droplet nuclei remain suspended in air currents for hours.
• Incubation Period: From infection to primary lesion development: 2 to 10 weeks. Risk of developing active clinical disease is highest within the first 1–2 years post-infection (lifetime risk is ~10%, increased dramatically to 10% per year in HIV-coinfected persons).

Epidemiological Indicators

Prevention & Immunity: BCG Vaccination

• Vaccine Strain: Live attenuated Mycobacterium bovis (Danish 1331 strain used in India).
• Dosage & Route:
  • < 1 Month of Age: 0.05 mL strictly intradermal.
  • 1 Month to 1 Year of Age: 0.1 mL strictly intradermal.
• Injection Site: Over the insertion of the left deltoid muscle (standardized globally to identify scar easily).
• Reconstitution: Freeze-dried powder reconstituted ONLY with sterile 0.9% Normal Saline. Distilled water must NEVER be used (causes tissue necrosis due to hypotonicity). Reconstituted vaccine must be used within 4 hours (risk of toxic shock syndrome due to Staphylococcus aureus contamination) and kept at +2°C to +8°C.
• Normal Vaccination Reaction: A papule develops at 2–3 weeks post-vaccination → indurates and forms a vesicle/pustule at 4–6 weeks → breaks down into a shallow ulcer at 6–8 weeks → heals spontaneously leaving a permanent depressed scar at 8–12 weeks (2–3 months).
• Protective Efficacy: High protective efficacy (70–80%) against severe childhood forms of TB (tubercular meningitis, miliary TB). Limited and variable efficacy (0–50%) against primary adult pulmonary TB.
• Complications: Suppurative lymphadenitis (most common), BCGoma, local ulceration, osteomyelitis, disseminated BCGosis (in severe immunodeficiency, e.g., congenital T-cell immunodeficiency or advanced HIV).

2. Malaria Epidemiology & Vector Dynamics in India

Etiological Agents & Species Distribution

• Plasmodium Species in India: Plasmodium vivax (~50–55%) and Plasmodium falciparum (~45–50%). P. malariae is rare (<1%, focally in Odisha/Tumkur), while P. ovale is exceedingly rare.
• Incubation Periods:
  • P. falciparum: 9–14 days (average 12 days).
  • P. vivax: 12–17 days (average 14 days, prolonged hypnozoite dormancy up to 9 months in temperate/tropical strains).
  • P. malariae: 18–40 days (average 28 days).
  • P. ovale: 16–18 days.

Anopheles Vector Dynamics in India

Vectors exhibit distinct eco-epidemiological niches critical for UPSC CMS questions:

• Anopheles culicifacies: Primary vector for rural malaria across the plains of India (70% of total cases). Breeds in clean riverbeds, irrigation channels, streams, and rainwater pools. Exophilic/endophilic, zoophilic.
• Anopheles stephensi: Primary vector for urban malaria. Breeds in artificial water containers, overhead tanks, cisterns, wells, and construction sites. Endophilic/endophagic, anthropophilic.
• Anopheles fluviatilis: Vector in hilly and forested tribal areas (especially Western Ghats and Central India). Highly anthropophilic, exophilic.
• Anopheles dirus: Vector in dense forest cover of North-Eastern states. Highly anthropophilic, early night biter.

Epidemiological Indices in Malaria Surveillance

• Annual Parasite Incidence (API): $\text{API} = \frac{\text{Total Confirmed Positive Malaria Cases in a Year}}{\text{Total Population Covered}} \times 1000$ Public Health Benchmark: API < 1 per 1,000 population is the threshold for a district to enter the Malaria Elimination Phase under the National Framework for Malaria Elimination (NFME).
• Annual Examination Rate (ABER): Percentage of total population examined for malaria parasites by blood slide/RDT in a year (target: ≥10% per year).
• Slide Positivity Rate (SPR): Percentage of blood slides examined that are positive for malaria parasites.
• Slide Falciparum Rate (SFR): Percentage of blood slides examined that are positive for P. falciparum.
• Infant Parasite Rate (IPR): Percentage of infants (<1 year old) positive for malaria parasites. IPR is the most sensitive indicator of recent and ongoing malaria transmission in a community.

Clinical Management Protocols

• Uncomplicated P. vivax Malaria:
  • Chloroquine: 25 mg/kg base total dose over 3 days (10 mg/kg Day 1, 10 mg/kg Day 2, 5 mg/kg Day 3).
  • Primaquine: 0.25 mg/kg daily for 14 days (radical cure to eliminate dormant liver hypnozoites and prevent relapse). Must screen for G6PD deficiency prior to administration to avoid acute intravascular hemolysis.
• Uncomplicated P. falciparum Malaria:
  • Rest of India: Artemisinin-based Combination Therapy - Artesunate (4 mg/kg daily for 3 days) + Sulfadoxine-Pyrimethamine (25 mg/kg Sulfadoxine / 1.25 mg/kg Pyrimethamine single dose on Day 1) [AS+SP] + Single dose Primaquine (0.75 mg/base/kg on Day 2 as gametocidal agent).
  • North-Eastern States: Artemether-Lumefantrine (AL) fixed-dose combination twice daily for 3 days + Single dose Primaquine (0.75 mg/kg) on Day 2 due to reported SP resistance in NE India.

---

3. Dengue Epidemiology & Entomological Control

Etiology & Pathogenesis

• Agent: Dengue Virus (DENV 1, DENV 2, DENV 3, DENV 4), a single-stranded RNA Flavivirus.
• Immunity: Primary infection induces lifelong immunity to the infecting serotype (homologous immunity), but only temporary, partial cross-protection (2–9 months) against other serotypes (heterologous immunity).
• Secondary Dengue & ADE: Secondary infection with a heterologous serotype (especially DENV-2 following DENV-1) carries a high risk of Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) via Antibody-Dependent Enhancement (ADE). Non-neutralizing heterologous antibodies bind to the new viral serotype, facilitating enhanced viral entry into monocytes/macrophages via Fc-gamma receptors, triggering massive pro-inflammatory cytokine release, vascular endothelial leakage, and severe thrombocytopenia.

Vector Characteristics: Aedes aegypti

• Morphology: Known as the "tiger mosquito" due to white lyre-shaped markings on its thorax and banded legs.
• Biting Behavior: Strictly daytime biter (bimodally active: peak biting early morning after sunrise and late afternoon before sunset).
• Breeding Habitats: Breeds strictly in clean, artificial water collections inside or near human dwellings (e.g., discarded tires, desert coolers, flower pots, plastic containers, roof gutters, cement tanks).
• Flight Range: Limited flight range (typically <100 meters), making localized vector control highly effective.

Entomological Surveillance Indices

Diagnostic Timelines & Critical Management

• Viremic / Febrile Phase (Days 1–5): NS1 Antigen ELISA / RDT is the test of choice (detectable from Day 1 to Day 5–7).
• Convalescent Phase (> Day 5): Dengue IgM Antibody ELISA becomes positive after Day 5 of illness.
• Critical Phase (Defervescence, Days 3–7): Marked by plasma leakage, hemoconcentration (hematocrit rise ≥20%), fluid accumulation (ascites, pleural effusion), thrombocytopenia (<100,000/mm³), and mucosal bleeding. Mainstay of therapy is judicious intravenous fluid resuscitation with isotonic crystalloids (e.g., Ringer's Lactate or 0.9% Normal Saline), titrated to maintain urine output ≥0.5–1 mL/kg/hour.